【摘要】：目的:探討四逆散加減對(duì)酒精性肝纖維化患者TGF-β、肝纖維化指標(biāo)及肝功能指標(biāo)的影響。方法:納入在2010年6月—2015年7月期間在醫(yī)院接受治療的酒精性肝纖維化患者122例,隨機(jī)分為對(duì)照組和治療組,各61例。兩組患者均口服水飛薊素片,多烯磷脂酰膽堿膠囊。觀(guān)察組在此基礎(chǔ)上口服四逆散加減湯劑,水煎煮至200 m L,日1劑,溫服。兩組患者均治療3個(gè)月。觀(guān)察兩組患者治療前后谷丙轉(zhuǎn)氨酶(ALT)、谷草轉(zhuǎn)氨酶(AST)、總膽紅素(TBIL)、谷氨酰轉(zhuǎn)移酶(GGT)、堿性磷酸酶(ALP)的變化水平;治療前后透明質(zhì)酸(HA)、III型前膠原(PCIII)、IV型膠原(IV-C)、層黏蛋白(LN)的變化水平;觀(guān)察兩組患者治療前后血清中金屬蛋白酶組織抑制劑1(TIMP-1)、轉(zhuǎn)化生長(zhǎng)因子β1(TGF-β1)的變化水平,記錄治療期間不良反應(yīng)發(fā)生情況。結(jié)果:治療組總有效率65.57%,對(duì)照組總有效率為59.01%,治療組顯著優(yōu)于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者治療前TBIL、ALT、AST、GGT、ALP比較無(wú)統(tǒng)計(jì)學(xué)差異(P0.05);兩組患者治療后各指標(biāo)均顯著改善,且均具有統(tǒng)計(jì)學(xué)差異(P0.05);且治療后觀(guān)察組各指標(biāo)改善情況均優(yōu)于對(duì)照組,結(jié)果具有統(tǒng)計(jì)學(xué)差異(P0.05);兩組患者治療前HA、PCIII、IV-C、LN比較無(wú)統(tǒng)計(jì)學(xué)差異(P0.05);兩組患者治療后各指標(biāo)均顯著改善,且均具有統(tǒng)計(jì)學(xué)差異(P0.05);且治療后觀(guān)察組各指標(biāo)改善情況均優(yōu)于對(duì)照組,結(jié)果具有統(tǒng)計(jì)學(xué)差異(P0.05);兩組患者治療前TIMP-1、TGF-β1比較無(wú)統(tǒng)計(jì)學(xué)差異(P0.05);兩組患者治療后上述指標(biāo)均顯著降低,且均具有統(tǒng)計(jì)學(xué)差異(P0.05);且治療后觀(guān)察組的指標(biāo)改善情況均優(yōu)于對(duì)照組,結(jié)果具有統(tǒng)計(jì)學(xué)差異(P0.05);對(duì)照組和治療組在治療中不良反應(yīng)發(fā)生情況相似,且未出現(xiàn)嚴(yán)重的不良反應(yīng),差異不具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:四逆散加減湯劑在治療酒精性肝纖維化中具有顯著的臨床療效,并可能是通過(guò)降低患者TGF-β1、TIMPs的表達(dá)來(lái)發(fā)揮作用,且無(wú)明顯不良反應(yīng)發(fā)生,臨床應(yīng)用安全可靠,具有重要臨床研究?jī)r(jià)值,值得進(jìn)一步推廣應(yīng)用。
[Abstract]:Aim: to study the effect of Sini San on TGF- 尾, liver fibrosis index and liver function index in alcoholic liver fibrosis patients. Methods: 122 patients with alcoholic liver fibrosis who were treated in hospital from June 2010 to July 2015 were randomly divided into control group and treatment group with 61 cases each. Both groups were treated with silymarin tablets and polyene phosphatidylcholine capsules. Observation group on this basis oral Sini San decoction, boiled to 200 mL, 1 dose per day, warm clothing. Both groups were treated for 3 months. Before and after treatment, the changes of alanine aminotransferase (ALT), total bilirubin (TBIL), glutamyltransferase (GGT),) and alkaline phosphatase (ALP) were observed. Changes of hyaluronic acid (HA), III procollagen type (PCIII), IV collagen (IV-C) and laminin (LN) before and after treatment; The serum levels of tissue inhibitor of metalloproteinase 1 (TIMP-1) and transforming growth factor 尾 1 (TGF- 尾 1) were observed before and after treatment. Results: the total effective rate of the treatment group was 65.57 and the total effective rate of the control group was 59.01. The treatment group was significantly better than the control group (P0.05). There was no significant difference in TBIL,ALT,AST,GGT,ALP between the two groups before treatment (P0.05); after treatment, the indexes of the two groups were significantly improved, and there was statistical difference between the two groups (P0.05). After treatment, the improvement of each index in the observation group was better than that in the control group, the results showed statistical difference (P0.05), and there was no significant difference in HA,PCIII,IV-C,LN between the two groups before treatment (P0.05). Two groups of patients after treatment were significantly improved, and have statistical differences (P0.05), and the observation group after treatment were better than the control group, the results were statistically significant (P0.05); There was no significant difference in TIMP-1,TGF- 尾 1 between the two groups before treatment (P0.05), and the above indexes were significantly decreased after treatment between the two groups (P0.05). After treatment, the improvement of the indexes in the observation group was better than that in the control group, and the results were statistically different (P0.05). Control group and treatment group in the treatment of adverse reactions occurred similar, and no serious adverse reactions, the difference was not statistically significant (P0.05). Conclusion: Sini San decoction has a significant clinical effect in the treatment of alcoholic liver fibrosis, and it may play a role by reducing the expression of TGF- 尾 _ 1 and TIMPs in patients, and no obvious adverse reactions occur. The clinical application is safe and reliable. It has important clinical research value and is worthy of further popularization and application.
【作者單位】： 臺(tái)州市第一人民醫(yī)院中醫(yī)科;
【分類(lèi)號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李耀林;四逆散加減治療失眠43例[J];廣西中醫(yī)學(xué)院學(xué)報(bào);2005年02期

2 張秀蘭;;四逆散加減應(yīng)用[J];內(nèi)蒙古中醫(yī)藥;1986年01期

3 黃冠群;;四逆散加減應(yīng)用[J];內(nèi)蒙古中醫(yī)藥;1992年01期

4 王春璞;四逆散加減治療慢性胃扭轉(zhuǎn)[J];實(shí)用中醫(yī)內(nèi)科雜志;1994年01期

5 王冠華;四逆散加減治療非潰瘍性消化不良[J];實(shí)用中醫(yī)內(nèi)科雜志;1996年02期

6 朱偉珍;丹梔四逆散加減治療十二指腸球部潰瘍50例效果觀(guān)察[J];右江醫(yī)學(xué);1996年02期

7 王世勛;;四逆散加減治療陽(yáng)痿56例[J];中國(guó)中醫(yī)藥科技;2007年01期

8 郭英;張國(guó)亭;;四逆散加減治療糖尿病陽(yáng)痿56例[J];中醫(yī)雜志;2007年06期

9 董桂芬;;四逆散加減治療脂肪肝60例觀(guān)察[J];實(shí)用中醫(yī)藥雜志;2008年04期

10 王志花;戴兆燕;錢(qián)耀華;黃培容;;四逆散加減治療消化性潰瘍63例[J];實(shí)用中醫(yī)內(nèi)科雜志;2012年06期

相關(guān)會(huì)議論文 前5條

1 宗世峰;宗世帥;;四逆散加減的臨床應(yīng)用[A];全國(guó)張仲景學(xué)術(shù)思想及醫(yī)方應(yīng)用研討會(huì)論文集[C];2001年

2 郭峰;;四逆散加減運(yùn)用四則[A];重慶市中醫(yī)藥學(xué)會(huì)學(xué)術(shù)年會(huì)論文集[C];2010年

3 丁世幸;;小陷胸湯合四逆散加減治療膽汁返流性胃炎36例[A];全國(guó)中醫(yī)藥科研與教學(xué)改革研討會(huì)論文集[C];2002年

4 景建中;羅敏;趙永嬌;;痛瀉要方合四逆散加減治療腸易激綜合癥的中醫(yī)臨證經(jīng)驗(yàn)[A];中國(guó)肛腸病研究心得集[C];2011年

5 景建中;羅敏;趙永嬌;;痛瀉要方合四逆散加減治療腸易激綜合癥的中醫(yī)臨證經(jīng)驗(yàn)[A];中國(guó)肛腸病研究心得集[C];2011年

相關(guān)重要報(bào)紙文章 前1條

1 整理 江蘇省中醫(yī)院名醫(yī)堂單兆偉名醫(yī)工作室 時(shí)樂(lè);柴芍護(hù)膜湯[N];中國(guó)中醫(yī)藥報(bào);2013年

相關(guān)碩士學(xué)位論文 前3條

1 張淑玲（CHANG SHU LIN）;四逆散加減方治療臺(tái)灣地區(qū)女性郁證郁結(jié)證臨床研究[D];廣州中醫(yī)藥大學(xué);2015年

2 王振興;四逆散加減方治療肝郁脾虛型失眠癥的臨床觀(guān)察[D];山東中醫(yī)藥大學(xué);2013年

3 王平勝;平胃散合四逆散加減治療慢性淺表性胃竇炎（脾胃濕熱證）的臨床研究[D];湖北中醫(yī)學(xué)院;2009年

，

本文編號(hào)：2342805